Hot Undervalued Stocks To Watch Right Now


Look no further than a market downturn when searching for the best buying opportunities. Investors looking at a historical chart of the S&P500 and pinpointing the best buying opportunities, it’s almost guaranteed that most of the best buying opportunities come during a bad market downturn or a recession. Thus, historically-speaking, now is an excellent opportunity to go shopping for oversold stocks as the downturn continues to deepen.

Recently-released inflation data was far from satisfactory, which likely means another oversized rate hike from the Federal Reserve. Of course, there is definitely some risk involved in buying stocks right now. That’s because stocks could have a lot of room to fall to the downside still. However, if you have a long-term outlook, this short-term turbulence should not scare you from taking advantage of deeply undervalued stocks.


For instance, I believe most technology stocks present a great buying opportunity. That’s because this downturn has hit this sector particularly hard. Tech stocks are highly risky during economic contractions, but they are equally rewarding when the economy expands. Therefore, I believe most of the following seven best buying opportunities right now are tech stocks.

Hot Undervalued Stocks To Watch Right Now: Bellerophon Therapeutics, Inc.(BLPH)

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates include INOpulse, a pulsatile nitric oxide delivery device, which has completed Phase II clinical trials for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.


Advisors’ Opinion:

  • [By Logan Wallace]

    ILLEGAL ACTIVITY WARNING: “Rothschild & Co. Asset Management US Inc. Increases Position in IBERIABANK Corp (IBKC)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at www.tickerreport.com/banking-finance/4146526/rothschild-co-asset-management-us-inc-increases-position-in-iberiabank-corp-ibkc.html.

  • [By Logan Wallace]

    Northern Trust Corp cut its holdings in shares of IBERIABANK Corp (NASDAQ:IBKC) by 35.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 743,718 shares of the bank’s stock after selling 401,090 shares during the period. Northern Trust Corp owned approximately 1.33% of IBERIABANK worth $56,374,000 as of its most recent filing with the Securities and Exchange Commission.

Hot Undervalued Stocks To Watch Right Now: Meridian Bioscience Inc.(VIVO)


Meridian Bioscience, Inc. (Meridian), incorporated on June 25, 1976, is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.


Diagnostics Segment

The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the United States and Canada (North America); Europe, Middle East and Africa (EMEA); and other countries outside of North America and EMEA (rest of the world). Meridian’s primary source of revenues continues to be diagnostic products, with its Diagnostics segment providing 77% of consolidated net sales for fiscal year ended September 30, 2013 (fiscal 2013). Third-party sales for this segment were $145,000 for fiscal 2013. The Company’s diagnostic products are used principally in the detection of infectious diseases caused by various bacteria, viruses, parasites and pathogens. It also operates a Diagnostics sales and distribution center near Milan in Italy.


Life Science Segment

The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including a sales and business development location in Singapore. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian’s Life Science segment focuses on the development, manufacture, sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturing companies, as well as contract development and manufacturing services under clinical cGMP conditions. Third-party sales for this segment were approximately $44,000 for fiscal 2013.


The Company has clinical cGMP protein production facility in Memphis, Tennessee. Immunodiagnostic products, such as antibodies, antigens and reagents are marketed to diagnostic manufacturing customers as a source of raw materials for their products, or as an outsourced step in their manufacturing processes. These products are sold in bulk quantities, and may also be custom-designed for a particular manufacturer’s requirements.

The Company competes with Cepheid, Becton Dickinson, Quidel, Great Basin, Nanosphere and Alere.

Advisors’ Opinion:

  • [By ]

    Ortho Clinical Diagnostics (NASDAQ:OCDX) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

  • [By Joseph Griffin]

    VIVO (CURRENCY:VIVO) traded up 50.3% against the U.S. dollar during the one day period ending at 18:00 PM ET on March 3rd. In the last week, VIVO has traded 35.9% higher against the U.S. dollar. VIVO has a market cap of $71,083.00 and approximately $336.00 worth of VIVO was traded on exchanges in the last day. One VIVO coin can currently be purchased for approximately $0.0192 or 0.00000501 BTC on exchanges including Stocks.Exchange, Cryptopia and CryptoBridge.

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY WARNING: “Meridian Bioscience, Inc. (VIVO) Holdings Reduced by Louisiana State Employees Retirement System” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at www.tickerreport.com/banking-finance/4129405/meridian-bioscience-inc-vivo-holdings-reduced-by-louisiana-state-employees-retirement-system.html.

  • [By Shane Hupp]

    Meridian Bioscience (NASDAQ:VIVO) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Hot Undervalued Stocks To Watch Right Now: Travelzoo Inc.(TZOO)

Travelzoo Inc., a media commerce company, together with its subsidiaries, provides travel, entertainment, and local deals from travel and entertainment companies, and local businesses in North America, Europe, and the Asia Pacific. Its publications and products include Travelzoo Websites, such as travelzoo.com, travelzoo.ca, travelzoo.co.uk, travelzoo.de, travelzoo.es, travelzoo.fr, cn.travelzoo.com, travelzoo.co.jp, travelzoo.com.au, travelzoo.com.hk, travelzoo.com.tw, and others; Travelzoo iPhone and Android applications; Travelzoo Top 20 e-mail newsletter; and Newsflash, an e-mail alert service. The company also operates SuperSearch, a pay-per-click travel search tool; the Travelzoo Network, a network of third-party Websites that list travel deals published by the company; Fly.com, a travel search engine that allows users to find the prices on flights from various airlines and online travel agencies; and Local Deals and Getaway services, which allow its subscribers to purchase vouchers for deals from local businesses, such as spas, hotels, and restaurants through the Travelzoo Website. It serves airlines, hotels, cruise lines, vacations packagers, tour operators, destinations, car rental companies, travel agents, theater and performing arts groups, restaurants, spas, and activity companies. The company was founded in 1998 and is headquartered in New York, New York.


Advisors’ Opinion:

  • [By ]

    Some of these are even smaller nano-caps, such as medical device maker Digirad (Nasdaq: DRAD), whose entire market value is just $36 million.

    There is absolutely nothing wrong with small businesses. I own shares of quite a few in my personal account. But for the most part, I use them to fill out the growth sleeve of my portfolio and don’t consider them stable income producers.

Leave a Reply

Your email address will not be published.